nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—skin cancer—psoriasis	0.496	1	CtDrD
Docetaxel—ABCC10—Cyclosporine—psoriasis	0.0337	0.104	CbGbCtD
Docetaxel—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0249	0.0765	CbGbCtD
Docetaxel—ABCC10—Methotrexate—psoriasis	0.0178	0.0549	CbGbCtD
Docetaxel—CYP3A5—Beclomethasone—psoriasis	0.016	0.0492	CbGbCtD
Docetaxel—ABCC1—Cyclosporine—psoriasis	0.013	0.0401	CbGbCtD
Docetaxel—ABCC2—Mycophenolate mofetil—psoriasis	0.0127	0.0391	CbGbCtD
Docetaxel—CYP1B1—Dexamethasone—psoriasis	0.0121	0.0371	CbGbCtD
Docetaxel—ABCG2—Mycophenolate mofetil—psoriasis	0.0115	0.0354	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—psoriasis	0.00997	0.0307	CbGbCtD
Docetaxel—ABCC2—Cyclosporine—psoriasis	0.00964	0.0297	CbGbCtD
Docetaxel—ABCG2—Hydrocortisone—psoriasis	0.00923	0.0284	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—psoriasis	0.00878	0.027	CbGbCtD
Docetaxel—ABCG2—Cyclosporine—psoriasis	0.00871	0.0268	CbGbCtD
Docetaxel—ABCC1—Methotrexate—psoriasis	0.00689	0.0212	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00681	0.021	CbGbCtD
Docetaxel—CYP3A7—Hydrocortisone—psoriasis	0.00681	0.021	CbGbCtD
Docetaxel—CYP3A7—Cyclosporine—psoriasis	0.00644	0.0198	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00644	0.0198	CbGbCtD
Docetaxel—CYP3A5—Mycophenolate mofetil—psoriasis	0.00637	0.0196	CbGbCtD
Docetaxel—ABCC2—Dexamethasone—psoriasis	0.00635	0.0195	CbGbCtD
Docetaxel—ABCG2—Dexamethasone—psoriasis	0.00574	0.0177	CbGbCtD
Docetaxel—CYP3A4—Calcitriol—psoriasis	0.00556	0.0171	CbGbCtD
Docetaxel—CYP3A5—Hydrocortisone—psoriasis	0.00511	0.0157	CbGbCtD
Docetaxel—ABCC2—Methotrexate—psoriasis	0.0051	0.0157	CbGbCtD
Docetaxel—CYP3A5—Cyclosporine—psoriasis	0.00483	0.0149	CbGbCtD
Docetaxel—ABCG2—Methotrexate—psoriasis	0.00461	0.0142	CbGbCtD
Docetaxel—CYP3A4—Methoxsalen—psoriasis	0.00432	0.0133	CbGbCtD
Docetaxel—CYP3A7—Dexamethasone—psoriasis	0.00424	0.013	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00424	0.013	CbGbCtD
Docetaxel—ABCB1—Mycophenolate mofetil—psoriasis	0.00415	0.0128	CbGbCtD
Docetaxel—ABCB1—Betamethasone—psoriasis	0.00356	0.0109	CbGbCtD
Docetaxel—ABCB1—Prednisolone—psoriasis	0.00351	0.0108	CbGbCtD
Docetaxel—ABCB1—Hydrocortisone—psoriasis	0.00333	0.0102	CbGbCtD
Docetaxel—ABCB1—Prednisone—psoriasis	0.00331	0.0102	CbGbCtD
Docetaxel—CYP3A5—Dexamethasone—psoriasis	0.00318	0.00978	CbGbCtD
Docetaxel—ABCB1—Cyclosporine—psoriasis	0.00314	0.00967	CbGbCtD
Docetaxel—CYP3A4—Cholecalciferol—psoriasis	0.00286	0.00881	CbGbCtD
Docetaxel—CYP3A4—Mycophenolate mofetil—psoriasis	0.00248	0.00764	CbGbCtD
Docetaxel—CYP3A4—Triamcinolone—psoriasis	0.00248	0.00764	CbGbCtD
Docetaxel—CYP3A4—Betamethasone—psoriasis	0.00213	0.00656	CbGbCtD
Docetaxel—CYP3A4—Prednisolone—psoriasis	0.0021	0.00647	CbGbCtD
Docetaxel—ABCB1—Dexamethasone—psoriasis	0.00207	0.00637	CbGbCtD
Docetaxel—CYP3A4—Hydrocortisone—psoriasis	0.00199	0.00613	CbGbCtD
Docetaxel—CYP3A4—Prednisone—psoriasis	0.00199	0.00611	CbGbCtD
Docetaxel—CYP3A4—Cyclosporine—psoriasis	0.00188	0.00579	CbGbCtD
Docetaxel—ABCB1—Methotrexate—psoriasis	0.00166	0.00512	CbGbCtD
Docetaxel—CYP3A4—Dexamethasone—psoriasis	0.00124	0.00381	CbGbCtD
Docetaxel—KIF11—tendon—psoriasis	0.000582	0.12	CbGeAlD
Docetaxel—BCL2—Tretinoin—Acitretin—psoriasis	0.000572	0.217	CbGdCrCtD
Docetaxel—BCL2—Isotretinoin—Acitretin—psoriasis	0.000572	0.217	CbGdCrCtD
Docetaxel—BCL2—Alitretinoin—Acitretin—psoriasis	0.000572	0.217	CbGdCrCtD
Docetaxel—TUBB4B—skin epidermis—psoriasis	0.00054	0.112	CbGeAlD
Docetaxel—MAP4—skin of body—psoriasis	0.000352	0.0729	CbGeAlD
Docetaxel—MAPT—tendon—psoriasis	0.000341	0.0706	CbGeAlD
Docetaxel—BCL2—skin of body—psoriasis	0.00032	0.0663	CbGeAlD
Docetaxel—TUBB6—Vitamin A—Acitretin—psoriasis	0.000297	0.113	CbGdCrCtD
Docetaxel—MAP4—tendon—psoriasis	0.000268	0.0555	CbGeAlD
Docetaxel—TUBB4A—skin of body—psoriasis	0.000214	0.0444	CbGeAlD
Docetaxel—MAP2—tendon—psoriasis	0.000211	0.0437	CbGeAlD
Docetaxel—TUBB6—Tretinoin—Acitretin—psoriasis	0.000207	0.0787	CbGdCrCtD
Docetaxel—TUBB6—Isotretinoin—Acitretin—psoriasis	0.000207	0.0787	CbGdCrCtD
Docetaxel—TUBB6—Alitretinoin—Acitretin—psoriasis	0.000207	0.0787	CbGdCrCtD
Docetaxel—TUBB2A—skin of body—psoriasis	0.000195	0.0404	CbGeAlD
Docetaxel—TUBB6—skin of body—psoriasis	0.000192	0.0398	CbGeAlD
Docetaxel—TUBB4B—skin of body—psoriasis	0.000167	0.0346	CbGeAlD
Docetaxel—TUBB4A—tendon—psoriasis	0.000163	0.0338	CbGeAlD
Docetaxel—TUBB2B—tendon—psoriasis	0.000158	0.0326	CbGeAlD
Docetaxel—TUBB—tendon—psoriasis	0.000149	0.0309	CbGeAlD
Docetaxel—TUBB2A—tendon—psoriasis	0.000149	0.0307	CbGeAlD
Docetaxel—TUBB6—tendon—psoriasis	0.000146	0.0303	CbGeAlD
Docetaxel—CYP1B1—skin of body—psoriasis	0.000133	0.0274	CbGeAlD
Docetaxel—ABCC10—tendon—psoriasis	0.000128	0.0265	CbGeAlD
Docetaxel—TUBB4B—tendon—psoriasis	0.000127	0.0263	CbGeAlD
Docetaxel—ABCC2—tendon—psoriasis	0.000103	0.0213	CbGeAlD
Docetaxel—CYP1B1—tendon—psoriasis	0.000101	0.0209	CbGeAlD
Docetaxel—ABCC1—tendon—psoriasis	9.07e-05	0.0188	CbGeAlD
Docetaxel—Dizziness—Mycophenolic acid—psoriasis	3.23e-05	0.000263	CcSEcCtD
Docetaxel—Epistaxis—Methotrexate—psoriasis	3.23e-05	0.000263	CcSEcCtD
Docetaxel—Paraesthesia—Prednisolone—psoriasis	3.23e-05	0.000263	CcSEcCtD
Docetaxel—Tachycardia—Triamcinolone—psoriasis	3.23e-05	0.000263	CcSEcCtD
Docetaxel—Mental disorder—Prednisone—psoriasis	3.23e-05	0.000263	CcSEcCtD
Docetaxel—Malnutrition—Prednisone—psoriasis	3.21e-05	0.000261	CcSEcCtD
Docetaxel—Erythema—Prednisone—psoriasis	3.21e-05	0.000261	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.2e-05	0.000261	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—psoriasis	3.2e-05	0.00026	CcSEcCtD
Docetaxel—Convulsion—Dexamethasone—psoriasis	3.19e-05	0.00026	CcSEcCtD
Docetaxel—Convulsion—Betamethasone—psoriasis	3.19e-05	0.00026	CcSEcCtD
Docetaxel—Feeling abnormal—Mycophenolate mofetil—psoriasis	3.18e-05	0.000259	CcSEcCtD
Docetaxel—Insomnia—Hydrocortisone—psoriasis	3.18e-05	0.000259	CcSEcCtD
Docetaxel—Hypertension—Dexamethasone—psoriasis	3.18e-05	0.000259	CcSEcCtD
Docetaxel—Hypertension—Betamethasone—psoriasis	3.18e-05	0.000259	CcSEcCtD
Docetaxel—Paraesthesia—Hydrocortisone—psoriasis	3.16e-05	0.000257	CcSEcCtD
Docetaxel—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	3.16e-05	0.000257	CcSEcCtD
Docetaxel—Myalgia—Betamethasone—psoriasis	3.13e-05	0.000255	CcSEcCtD
Docetaxel—Myalgia—Dexamethasone—psoriasis	3.13e-05	0.000255	CcSEcCtD
Docetaxel—Body temperature increased—Cyclosporine—psoriasis	3.13e-05	0.000254	CcSEcCtD
Docetaxel—Abdominal pain—Cyclosporine—psoriasis	3.13e-05	0.000254	CcSEcCtD
Docetaxel—Vomiting—Mycophenolic acid—psoriasis	3.11e-05	0.000253	CcSEcCtD
Docetaxel—Dyspepsia—Hydrocortisone—psoriasis	3.1e-05	0.000252	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—psoriasis	3.09e-05	0.000252	CcSEcCtD
Docetaxel—Rash—Mycophenolic acid—psoriasis	3.08e-05	0.000251	CcSEcCtD
Docetaxel—Dermatitis—Mycophenolic acid—psoriasis	3.08e-05	0.000251	CcSEcCtD
Docetaxel—Pain—Prednisolone—psoriasis	3.08e-05	0.000251	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—psoriasis	3.08e-05	0.00025	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—psoriasis	3.08e-05	0.00025	CcSEcCtD
Docetaxel—Headache—Mycophenolic acid—psoriasis	3.06e-05	0.000249	CcSEcCtD
Docetaxel—Decreased appetite—Hydrocortisone—psoriasis	3.06e-05	0.000249	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—psoriasis	3.06e-05	0.000249	CcSEcCtD
Docetaxel—Abdominal pain—Mycophenolate mofetil—psoriasis	3.05e-05	0.000248	CcSEcCtD
Docetaxel—Body temperature increased—Mycophenolate mofetil—psoriasis	3.05e-05	0.000248	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—psoriasis	3.04e-05	0.000247	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.04e-05	0.000247	CcSEcCtD
Docetaxel—Fatigue—Hydrocortisone—psoriasis	3.03e-05	0.000247	CcSEcCtD
Docetaxel—Urethral disorder—Methotrexate—psoriasis	3.02e-05	0.000245	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.02e-05	0.000245	CcSEcCtD
Docetaxel—Pain—Hydrocortisone—psoriasis	3.01e-05	0.000245	CcSEcCtD
Docetaxel—Anaphylactic shock—Betamethasone—psoriasis	3e-05	0.000244	CcSEcCtD
Docetaxel—Oedema—Betamethasone—psoriasis	3e-05	0.000244	CcSEcCtD
Docetaxel—Anaphylactic shock—Dexamethasone—psoriasis	3e-05	0.000244	CcSEcCtD
Docetaxel—Oedema—Dexamethasone—psoriasis	3e-05	0.000244	CcSEcCtD
Docetaxel—Insomnia—Triamcinolone—psoriasis	3e-05	0.000244	CcSEcCtD
Docetaxel—Infection—Dexamethasone—psoriasis	2.99e-05	0.000243	CcSEcCtD
Docetaxel—Infection—Betamethasone—psoriasis	2.99e-05	0.000243	CcSEcCtD
Docetaxel—Paraesthesia—Triamcinolone—psoriasis	2.97e-05	0.000242	CcSEcCtD
Docetaxel—Feeling abnormal—Prednisolone—psoriasis	2.97e-05	0.000241	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—psoriasis	2.97e-05	0.000241	CcSEcCtD
Docetaxel—Anaemia—Prednisone—psoriasis	2.96e-05	0.000241	CcSEcCtD
Docetaxel—Shock—Dexamethasone—psoriasis	2.96e-05	0.00024	CcSEcCtD
Docetaxel—Shock—Betamethasone—psoriasis	2.96e-05	0.00024	CcSEcCtD
Docetaxel—Dyspnoea—Triamcinolone—psoriasis	2.95e-05	0.00024	CcSEcCtD
Docetaxel—Nervous system disorder—Dexamethasone—psoriasis	2.95e-05	0.00024	CcSEcCtD
Docetaxel—Nervous system disorder—Betamethasone—psoriasis	2.95e-05	0.00024	CcSEcCtD
Docetaxel—Thrombocytopenia—Dexamethasone—psoriasis	2.94e-05	0.000239	CcSEcCtD
Docetaxel—Thrombocytopenia—Betamethasone—psoriasis	2.94e-05	0.000239	CcSEcCtD
Docetaxel—Tachycardia—Dexamethasone—psoriasis	2.93e-05	0.000239	CcSEcCtD
Docetaxel—Tachycardia—Betamethasone—psoriasis	2.93e-05	0.000239	CcSEcCtD
Docetaxel—Hypersensitivity—Cyclosporine—psoriasis	2.92e-05	0.000237	CcSEcCtD
Docetaxel—Dyspepsia—Triamcinolone—psoriasis	2.92e-05	0.000237	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—psoriasis	2.91e-05	0.000237	CcSEcCtD
Docetaxel—Nausea—Mycophenolic acid—psoriasis	2.91e-05	0.000236	CcSEcCtD
Docetaxel—Feeling abnormal—Hydrocortisone—psoriasis	2.9e-05	0.000236	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—psoriasis	2.88e-05	0.000234	CcSEcCtD
Docetaxel—Gastrointestinal pain—Hydrocortisone—psoriasis	2.88e-05	0.000234	CcSEcCtD
Docetaxel—Syncope—Prednisone—psoriasis	2.88e-05	0.000234	CcSEcCtD
Docetaxel—Anorexia—Dexamethasone—psoriasis	2.86e-05	0.000233	CcSEcCtD
Docetaxel—Anorexia—Betamethasone—psoriasis	2.86e-05	0.000233	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—psoriasis	2.86e-05	0.000232	CcSEcCtD
Docetaxel—Fatigue—Triamcinolone—psoriasis	2.86e-05	0.000232	CcSEcCtD
Docetaxel—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.84e-05	0.000231	CcSEcCtD
Docetaxel—Asthenia—Cyclosporine—psoriasis	2.84e-05	0.000231	CcSEcCtD
Docetaxel—Pain—Triamcinolone—psoriasis	2.83e-05	0.00023	CcSEcCtD
Docetaxel—Loss of consciousness—Prednisone—psoriasis	2.82e-05	0.000229	CcSEcCtD
Docetaxel—Hypotension—Dexamethasone—psoriasis	2.81e-05	0.000228	CcSEcCtD
Docetaxel—Hypotension—Betamethasone—psoriasis	2.81e-05	0.000228	CcSEcCtD
Docetaxel—Pruritus—Cyclosporine—psoriasis	2.8e-05	0.000228	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—psoriasis	2.79e-05	0.000227	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—psoriasis	2.78e-05	0.000226	CcSEcCtD
Docetaxel—Abdominal pain—Hydrocortisone—psoriasis	2.78e-05	0.000226	CcSEcCtD
Docetaxel—Body temperature increased—Hydrocortisone—psoriasis	2.78e-05	0.000226	CcSEcCtD
Docetaxel—Convulsion—Prednisone—psoriasis	2.78e-05	0.000226	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—psoriasis	2.77e-05	0.000226	CcSEcCtD
Docetaxel—Asthenia—Mycophenolate mofetil—psoriasis	2.77e-05	0.000225	CcSEcCtD
Docetaxel—Hypertension—Prednisone—psoriasis	2.77e-05	0.000225	CcSEcCtD
Docetaxel—Chills—Methotrexate—psoriasis	2.76e-05	0.000225	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Betamethasone—psoriasis	2.74e-05	0.000223	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.74e-05	0.000223	CcSEcCtD
Docetaxel—Pruritus—Mycophenolate mofetil—psoriasis	2.73e-05	0.000222	CcSEcCtD
Docetaxel—Arthralgia—Prednisone—psoriasis	2.73e-05	0.000222	CcSEcCtD
Docetaxel—Myalgia—Prednisone—psoriasis	2.73e-05	0.000222	CcSEcCtD
Docetaxel—Feeling abnormal—Triamcinolone—psoriasis	2.73e-05	0.000222	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—psoriasis	2.72e-05	0.000221	CcSEcCtD
Docetaxel—Insomnia—Dexamethasone—psoriasis	2.72e-05	0.000221	CcSEcCtD
Docetaxel—Insomnia—Betamethasone—psoriasis	2.72e-05	0.000221	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.71e-05	0.000221	CcSEcCtD
Docetaxel—Diarrhoea—Cyclosporine—psoriasis	2.71e-05	0.00022	CcSEcCtD
Docetaxel—Paraesthesia—Betamethasone—psoriasis	2.7e-05	0.000219	CcSEcCtD
Docetaxel—Paraesthesia—Dexamethasone—psoriasis	2.7e-05	0.000219	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—psoriasis	2.7e-05	0.000219	CcSEcCtD
Docetaxel—Erythema—Methotrexate—psoriasis	2.68e-05	0.000218	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—psoriasis	2.68e-05	0.000218	CcSEcCtD
Docetaxel—Hypersensitivity—Prednisolone—psoriasis	2.65e-05	0.000216	CcSEcCtD
Docetaxel—Dyspepsia—Dexamethasone—psoriasis	2.65e-05	0.000215	CcSEcCtD
Docetaxel—Dyspepsia—Betamethasone—psoriasis	2.65e-05	0.000215	CcSEcCtD
Docetaxel—Diarrhoea—Mycophenolate mofetil—psoriasis	2.64e-05	0.000215	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—psoriasis	2.62e-05	0.000213	CcSEcCtD
Docetaxel—Body temperature increased—Triamcinolone—psoriasis	2.62e-05	0.000213	CcSEcCtD
Docetaxel—Dizziness—Cyclosporine—psoriasis	2.62e-05	0.000213	CcSEcCtD
Docetaxel—Anaphylactic shock—Prednisone—psoriasis	2.62e-05	0.000213	CcSEcCtD
Docetaxel—Oedema—Prednisone—psoriasis	2.62e-05	0.000213	CcSEcCtD
Docetaxel—Decreased appetite—Dexamethasone—psoriasis	2.61e-05	0.000212	CcSEcCtD
Docetaxel—Decreased appetite—Betamethasone—psoriasis	2.61e-05	0.000212	CcSEcCtD
Docetaxel—Infection—Prednisone—psoriasis	2.6e-05	0.000211	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Dexamethasone—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Betamethasone—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Back pain—Methotrexate—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Hypersensitivity—Hydrocortisone—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Fatigue—Dexamethasone—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Fatigue—Betamethasone—psoriasis	2.59e-05	0.000211	CcSEcCtD
Docetaxel—Shock—Prednisone—psoriasis	2.57e-05	0.000209	CcSEcCtD
Docetaxel—Pain—Dexamethasone—psoriasis	2.57e-05	0.000209	CcSEcCtD
Docetaxel—Pain—Betamethasone—psoriasis	2.57e-05	0.000209	CcSEcCtD
Docetaxel—Nervous system disorder—Prednisone—psoriasis	2.57e-05	0.000209	CcSEcCtD
Docetaxel—Tachycardia—Prednisone—psoriasis	2.55e-05	0.000208	CcSEcCtD
Docetaxel—Dizziness—Mycophenolate mofetil—psoriasis	2.55e-05	0.000208	CcSEcCtD
Docetaxel—Skin disorder—Prednisone—psoriasis	2.54e-05	0.000207	CcSEcCtD
Docetaxel—Asthenia—Hydrocortisone—psoriasis	2.52e-05	0.000205	CcSEcCtD
Docetaxel—Vomiting—Cyclosporine—psoriasis	2.52e-05	0.000205	CcSEcCtD
Docetaxel—Rash—Cyclosporine—psoriasis	2.5e-05	0.000203	CcSEcCtD
Docetaxel—Anorexia—Prednisone—psoriasis	2.49e-05	0.000203	CcSEcCtD
Docetaxel—Dermatitis—Cyclosporine—psoriasis	2.49e-05	0.000203	CcSEcCtD
Docetaxel—Pruritus—Hydrocortisone—psoriasis	2.49e-05	0.000202	CcSEcCtD
Docetaxel—Headache—Cyclosporine—psoriasis	2.48e-05	0.000202	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—psoriasis	2.48e-05	0.000201	CcSEcCtD
Docetaxel—Feeling abnormal—Betamethasone—psoriasis	2.48e-05	0.000201	CcSEcCtD
Docetaxel—Feeling abnormal—Dexamethasone—psoriasis	2.48e-05	0.000201	CcSEcCtD
Docetaxel—Gastrointestinal pain—Betamethasone—psoriasis	2.46e-05	0.0002	CcSEcCtD
Docetaxel—Gastrointestinal pain—Dexamethasone—psoriasis	2.46e-05	0.0002	CcSEcCtD
Docetaxel—Vomiting—Mycophenolate mofetil—psoriasis	2.45e-05	0.0002	CcSEcCtD
Docetaxel—Hypersensitivity—Triamcinolone—psoriasis	2.44e-05	0.000198	CcSEcCtD
Docetaxel—Rash—Mycophenolate mofetil—psoriasis	2.43e-05	0.000198	CcSEcCtD
Docetaxel—Dermatitis—Mycophenolate mofetil—psoriasis	2.43e-05	0.000198	CcSEcCtD
Docetaxel—Headache—Mycophenolate mofetil—psoriasis	2.42e-05	0.000197	CcSEcCtD
Docetaxel—Diarrhoea—Hydrocortisone—psoriasis	2.41e-05	0.000196	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—psoriasis	2.4e-05	0.000195	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Prednisone—psoriasis	2.38e-05	0.000194	CcSEcCtD
Docetaxel—Dizziness—Prednisolone—psoriasis	2.38e-05	0.000194	CcSEcCtD
Docetaxel—Asthenia—Triamcinolone—psoriasis	2.38e-05	0.000193	CcSEcCtD
Docetaxel—Body temperature increased—Dexamethasone—psoriasis	2.38e-05	0.000193	CcSEcCtD
Docetaxel—Body temperature increased—Betamethasone—psoriasis	2.38e-05	0.000193	CcSEcCtD
Docetaxel—Abdominal pain—Betamethasone—psoriasis	2.38e-05	0.000193	CcSEcCtD
Docetaxel—Abdominal pain—Dexamethasone—psoriasis	2.38e-05	0.000193	CcSEcCtD
Docetaxel—Insomnia—Prednisone—psoriasis	2.37e-05	0.000193	CcSEcCtD
Docetaxel—Nausea—Cyclosporine—psoriasis	2.35e-05	0.000191	CcSEcCtD
Docetaxel—Paraesthesia—Prednisone—psoriasis	2.35e-05	0.000191	CcSEcCtD
Docetaxel—Pruritus—Triamcinolone—psoriasis	2.34e-05	0.000191	CcSEcCtD
Docetaxel—Cough—Methotrexate—psoriasis	2.34e-05	0.00019	CcSEcCtD
Docetaxel—Dizziness—Hydrocortisone—psoriasis	2.33e-05	0.000189	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—psoriasis	2.32e-05	0.000189	CcSEcCtD
Docetaxel—Dyspepsia—Prednisone—psoriasis	2.3e-05	0.000187	CcSEcCtD
Docetaxel—Nausea—Mycophenolate mofetil—psoriasis	2.29e-05	0.000187	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—psoriasis	2.28e-05	0.000186	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—psoriasis	2.28e-05	0.000186	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—psoriasis	2.28e-05	0.000186	CcSEcCtD
Docetaxel—Decreased appetite—Prednisone—psoriasis	2.27e-05	0.000185	CcSEcCtD
Docetaxel—Rash—Prednisolone—psoriasis	2.27e-05	0.000185	CcSEcCtD
Docetaxel—Dermatitis—Prednisolone—psoriasis	2.27e-05	0.000185	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.27e-05	0.000184	CcSEcCtD
Docetaxel—Fatigue—Prednisone—psoriasis	2.26e-05	0.000184	CcSEcCtD
Docetaxel—Headache—Prednisolone—psoriasis	2.26e-05	0.000184	CcSEcCtD
Docetaxel—Constipation—Prednisone—psoriasis	2.24e-05	0.000182	CcSEcCtD
Docetaxel—Vomiting—Hydrocortisone—psoriasis	2.24e-05	0.000182	CcSEcCtD
Docetaxel—Rash—Hydrocortisone—psoriasis	2.22e-05	0.00018	CcSEcCtD
Docetaxel—Dermatitis—Hydrocortisone—psoriasis	2.22e-05	0.00018	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—psoriasis	2.21e-05	0.000179	CcSEcCtD
Docetaxel—Headache—Hydrocortisone—psoriasis	2.2e-05	0.000179	CcSEcCtD
Docetaxel—Dizziness—Triamcinolone—psoriasis	2.19e-05	0.000178	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—psoriasis	2.19e-05	0.000178	CcSEcCtD
Docetaxel—Infection—Methotrexate—psoriasis	2.17e-05	0.000177	CcSEcCtD
Docetaxel—Feeling abnormal—Prednisone—psoriasis	2.16e-05	0.000175	CcSEcCtD
Docetaxel—Asthenia—Betamethasone—psoriasis	2.16e-05	0.000175	CcSEcCtD
Docetaxel—Asthenia—Dexamethasone—psoriasis	2.16e-05	0.000175	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—psoriasis	2.14e-05	0.000174	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—psoriasis	2.14e-05	0.000174	CcSEcCtD
Docetaxel—Gastrointestinal pain—Prednisone—psoriasis	2.14e-05	0.000174	CcSEcCtD
Docetaxel—Nausea—Prednisolone—psoriasis	2.14e-05	0.000174	CcSEcCtD
Docetaxel—Pruritus—Betamethasone—psoriasis	2.13e-05	0.000173	CcSEcCtD
Docetaxel—Pruritus—Dexamethasone—psoriasis	2.13e-05	0.000173	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—psoriasis	2.12e-05	0.000173	CcSEcCtD
Docetaxel—Vomiting—Triamcinolone—psoriasis	2.11e-05	0.000171	CcSEcCtD
Docetaxel—Nausea—Hydrocortisone—psoriasis	2.09e-05	0.00017	CcSEcCtD
Docetaxel—Rash—Triamcinolone—psoriasis	2.09e-05	0.00017	CcSEcCtD
Docetaxel—Dermatitis—Triamcinolone—psoriasis	2.09e-05	0.00017	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—psoriasis	2.08e-05	0.00017	CcSEcCtD
Docetaxel—Headache—Triamcinolone—psoriasis	2.07e-05	0.000169	CcSEcCtD
Docetaxel—Body temperature increased—Prednisone—psoriasis	2.07e-05	0.000168	CcSEcCtD
Docetaxel—Abdominal pain—Prednisone—psoriasis	2.07e-05	0.000168	CcSEcCtD
Docetaxel—EGFR—Adaptive Immune System—HLA-C—psoriasis	2.06e-05	0.000424	CbGpPWpGaD
Docetaxel—Diarrhoea—Betamethasone—psoriasis	2.06e-05	0.000167	CcSEcCtD
Docetaxel—Diarrhoea—Dexamethasone—psoriasis	2.06e-05	0.000167	CcSEcCtD
Docetaxel—TUBB3—Metabolism of proteins—LEP—psoriasis	2.05e-05	0.000421	CbGpPWpGaD
Docetaxel—Hypotension—Methotrexate—psoriasis	2.04e-05	0.000166	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—psoriasis	1.99e-05	0.000162	CcSEcCtD
Docetaxel—Dizziness—Dexamethasone—psoriasis	1.99e-05	0.000162	CcSEcCtD
Docetaxel—Dizziness—Betamethasone—psoriasis	1.99e-05	0.000162	CcSEcCtD
Docetaxel—TUBB2A—Metabolism of proteins—LEP—psoriasis	1.98e-05	0.000408	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—JUN—psoriasis	1.98e-05	0.000408	CbGpPWpGaD
Docetaxel—Insomnia—Methotrexate—psoriasis	1.98e-05	0.000161	CcSEcCtD
Docetaxel—ABCG2—Metabolism—CYP2S1—psoriasis	1.98e-05	0.000407	CbGpPWpGaD
Docetaxel—Nausea—Triamcinolone—psoriasis	1.97e-05	0.00016	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—psoriasis	1.96e-05	0.00016	CcSEcCtD
Docetaxel—CYP3A7—Metabolism—CYP2S1—psoriasis	1.96e-05	0.000403	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—HCAR2—psoriasis	1.96e-05	0.000403	CbGpPWpGaD
Docetaxel—Dyspnoea—Methotrexate—psoriasis	1.95e-05	0.000159	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—psoriasis	1.94e-05	0.000158	CcSEcCtD
Docetaxel—ABCB1—Allograft Rejection—IFNG—psoriasis	1.94e-05	0.0004	CbGpPWpGaD
Docetaxel—TUBB1—Metabolism of proteins—LEP—psoriasis	1.94e-05	0.000399	CbGpPWpGaD
Docetaxel—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.94e-05	0.000399	CbGpPWpGaD
Docetaxel—Hypersensitivity—Prednisone—psoriasis	1.93e-05	0.000157	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—psoriasis	1.93e-05	0.000157	CcSEcCtD
Docetaxel—EGFR—Immune System—DDX58—psoriasis	1.92e-05	0.000394	CbGpPWpGaD
Docetaxel—Vomiting—Betamethasone—psoriasis	1.91e-05	0.000155	CcSEcCtD
Docetaxel—Vomiting—Dexamethasone—psoriasis	1.91e-05	0.000155	CcSEcCtD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	1.91e-05	0.000393	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	1.91e-05	0.000392	CbGpPWpGaD
Docetaxel—Decreased appetite—Methotrexate—psoriasis	1.9e-05	0.000155	CcSEcCtD
Docetaxel—BCL2—Innate Immune System—CRP—psoriasis	1.9e-05	0.00039	CbGpPWpGaD
Docetaxel—Rash—Dexamethasone—psoriasis	1.89e-05	0.000154	CcSEcCtD
Docetaxel—Rash—Betamethasone—psoriasis	1.89e-05	0.000154	CcSEcCtD
Docetaxel—Dermatitis—Dexamethasone—psoriasis	1.89e-05	0.000154	CcSEcCtD
Docetaxel—Dermatitis—Betamethasone—psoriasis	1.89e-05	0.000154	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—psoriasis	1.89e-05	0.000154	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—psoriasis	1.89e-05	0.000153	CcSEcCtD
Docetaxel—Headache—Dexamethasone—psoriasis	1.88e-05	0.000153	CcSEcCtD
Docetaxel—Headache—Betamethasone—psoriasis	1.88e-05	0.000153	CcSEcCtD
Docetaxel—Asthenia—Prednisone—psoriasis	1.88e-05	0.000153	CcSEcCtD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—JUN—psoriasis	1.87e-05	0.000385	CbGpPWpGaD
Docetaxel—Pain—Methotrexate—psoriasis	1.87e-05	0.000152	CcSEcCtD
Docetaxel—Pruritus—Prednisone—psoriasis	1.85e-05	0.000151	CcSEcCtD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.84e-05	0.00038	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.83e-05	0.000377	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—JUN—psoriasis	1.82e-05	0.000374	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—STAT3—psoriasis	1.81e-05	0.000373	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—TNF—psoriasis	1.81e-05	0.000372	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.81e-05	0.000372	CbGpPWpGaD
Docetaxel—Feeling abnormal—Methotrexate—psoriasis	1.8e-05	0.000147	CcSEcCtD
Docetaxel—EGFR—Signaling by NGF—NFKBIA—psoriasis	1.79e-05	0.000369	CbGpPWpGaD
Docetaxel—Diarrhoea—Prednisone—psoriasis	1.79e-05	0.000146	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—psoriasis	1.79e-05	0.000145	CcSEcCtD
Docetaxel—Nausea—Dexamethasone—psoriasis	1.78e-05	0.000145	CcSEcCtD
Docetaxel—Nausea—Betamethasone—psoriasis	1.78e-05	0.000145	CcSEcCtD
Docetaxel—EGFR—Innate Immune System—HLA-E—psoriasis	1.78e-05	0.000366	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	1.76e-05	0.000362	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-E—psoriasis	1.75e-05	0.000361	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—NFKB1—psoriasis	1.75e-05	0.00036	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	1.74e-05	0.000359	CbGpPWpGaD
Docetaxel—TUBB4A—Metabolism of proteins—LEP—psoriasis	1.74e-05	0.000358	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—TYK2—psoriasis	1.74e-05	0.000357	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	1.73e-05	0.000356	CbGpPWpGaD
Docetaxel—Dizziness—Prednisone—psoriasis	1.73e-05	0.000141	CcSEcCtD
Docetaxel—BCL2—Innate Immune System—NFKBIA—psoriasis	1.73e-05	0.000356	CbGpPWpGaD
Docetaxel—Abdominal pain—Methotrexate—psoriasis	1.73e-05	0.000141	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—psoriasis	1.73e-05	0.000141	CcSEcCtD
Docetaxel—EGFR—Signaling by GPCR—CCL20—psoriasis	1.72e-05	0.000354	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-E—psoriasis	1.71e-05	0.000352	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TAGAP—psoriasis	1.7e-05	0.000349	CbGpPWpGaD
Docetaxel—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.69e-05	0.000349	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	1.68e-05	0.000346	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NDUFA5—psoriasis	1.67e-05	0.000343	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.67e-05	0.000343	CbGpPWpGaD
Docetaxel—Vomiting—Prednisone—psoriasis	1.66e-05	0.000135	CcSEcCtD
Docetaxel—Rash—Prednisone—psoriasis	1.65e-05	0.000134	CcSEcCtD
Docetaxel—EGFR—Focal Adhesion—JUN—psoriasis	1.65e-05	0.000339	CbGpPWpGaD
Docetaxel—Dermatitis—Prednisone—psoriasis	1.65e-05	0.000134	CcSEcCtD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.64e-05	0.000338	CbGpPWpGaD
Docetaxel—Headache—Prednisone—psoriasis	1.64e-05	0.000133	CcSEcCtD
Docetaxel—EGFR—Downstream signal transduction—STAT3—psoriasis	1.63e-05	0.000335	CbGpPWpGaD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	1.62e-05	0.000333	CbGpPWpGaD
Docetaxel—Hypersensitivity—Methotrexate—psoriasis	1.61e-05	0.000131	CcSEcCtD
Docetaxel—EGFR—Spinal Cord Injury—TP53—psoriasis	1.59e-05	0.000328	CbGpPWpGaD
Docetaxel—TUBB4B—Metabolism of proteins—LEP—psoriasis	1.59e-05	0.000328	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.58e-05	0.000325	CbGpPWpGaD
Docetaxel—Asthenia—Methotrexate—psoriasis	1.57e-05	0.000128	CcSEcCtD
Docetaxel—Nausea—Prednisone—psoriasis	1.55e-05	0.000126	CcSEcCtD
Docetaxel—EGFR—B Cell Activation—NFKB1—psoriasis	1.55e-05	0.00032	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—CARM1—psoriasis	1.55e-05	0.000319	CbGpPWpGaD
Docetaxel—Pruritus—Methotrexate—psoriasis	1.55e-05	0.000126	CcSEcCtD
Docetaxel—KIF11—Immune System—IL6—psoriasis	1.54e-05	0.000318	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—CXCL8—psoriasis	1.51e-05	0.000311	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—STAT3—psoriasis	1.51e-05	0.000311	CbGpPWpGaD
Docetaxel—Diarrhoea—Methotrexate—psoriasis	1.5e-05	0.000122	CcSEcCtD
Docetaxel—NR1I2—Gene Expression—PPARG—psoriasis	1.49e-05	0.000306	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.49e-05	0.000306	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—SOCS1—psoriasis	1.49e-05	0.000306	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—STAT3—psoriasis	1.48e-05	0.000304	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—TYK2—psoriasis	1.47e-05	0.000302	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.47e-05	0.000302	CbGpPWpGaD
Docetaxel—BCL2—Immune System—SOCS1—psoriasis	1.46e-05	0.000301	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—IL6—psoriasis	1.46e-05	0.0003	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ITGAL—psoriasis	1.45e-05	0.000299	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.45e-05	0.000298	CbGpPWpGaD
Docetaxel—Dizziness—Methotrexate—psoriasis	1.45e-05	0.000118	CcSEcCtD
Docetaxel—EGFR—Focal Adhesion—VEGFA—psoriasis	1.44e-05	0.000296	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—IL6—psoriasis	1.44e-05	0.000296	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.43e-05	0.000295	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—SOCS1—psoriasis	1.43e-05	0.000294	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—TYK2—psoriasis	1.42e-05	0.000292	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CYP2S1—psoriasis	1.42e-05	0.000291	CbGpPWpGaD
Docetaxel—TUBB2B—Metabolism of proteins—CXCL8—psoriasis	1.41e-05	0.00029	CbGpPWpGaD
Docetaxel—TUBB6—Metabolism of proteins—CXCL8—psoriasis	1.41e-05	0.00029	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—JUN—psoriasis	1.41e-05	0.000289	CbGpPWpGaD
Docetaxel—Vomiting—Methotrexate—psoriasis	1.39e-05	0.000113	CcSEcCtD
Docetaxel—EGFR—Direct p53 effectors—TP53—psoriasis	1.39e-05	0.000286	CbGpPWpGaD
Docetaxel—Rash—Methotrexate—psoriasis	1.38e-05	0.000112	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—psoriasis	1.38e-05	0.000112	CcSEcCtD
Docetaxel—Headache—Methotrexate—psoriasis	1.37e-05	0.000111	CcSEcCtD
Docetaxel—EGFR—MAPK Signaling Pathway—TNF—psoriasis	1.36e-05	0.00028	CbGpPWpGaD
Docetaxel—TUBB3—Metabolism of proteins—CXCL8—psoriasis	1.36e-05	0.00028	CbGpPWpGaD
Docetaxel—EGFR—Immune System—REL—psoriasis	1.36e-05	0.000279	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—NFKB1—psoriasis	1.35e-05	0.000278	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	1.34e-05	0.000275	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—TYK2—psoriasis	1.33e-05	0.000273	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IFIH1—psoriasis	1.32e-05	0.000271	CbGpPWpGaD
Docetaxel—TUBB2A—Metabolism of proteins—CXCL8—psoriasis	1.32e-05	0.000271	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.31e-05	0.000269	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CD8A—psoriasis	1.3e-05	0.000267	CbGpPWpGaD
Docetaxel—Nausea—Methotrexate—psoriasis	1.3e-05	0.000106	CcSEcCtD
Docetaxel—TUBB1—Metabolism of proteins—CXCL8—psoriasis	1.29e-05	0.000265	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—CD4—psoriasis	1.28e-05	0.000264	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HLA-B—psoriasis	1.27e-05	0.000261	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—CD8A—psoriasis	1.27e-05	0.000261	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—IL6—psoriasis	1.26e-05	0.00026	CbGpPWpGaD
Docetaxel—ABCB1—Allograft Rejection—TNF—psoriasis	1.26e-05	0.000259	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NDUFA5—psoriasis	1.26e-05	0.000259	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.25e-05	0.000257	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-B—psoriasis	1.25e-05	0.000257	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-C—psoriasis	1.25e-05	0.000257	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—LEP—psoriasis	1.24e-05	0.000256	CbGpPWpGaD
Docetaxel—EGFR—Immune System—TNFAIP3—psoriasis	1.23e-05	0.000254	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.23e-05	0.000253	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—VEGFA—psoriasis	1.23e-05	0.000253	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-B—psoriasis	1.22e-05	0.000251	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—STAT3—psoriasis	1.22e-05	0.00025	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—IL6—psoriasis	1.21e-05	0.000249	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—TP53—psoriasis	1.2e-05	0.000247	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—IL6—psoriasis	1.19e-05	0.000245	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.18e-05	0.000242	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.17e-05	0.00024	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-A—psoriasis	1.16e-05	0.000238	CbGpPWpGaD
Docetaxel—TUBB4A—Metabolism of proteins—CXCL8—psoriasis	1.16e-05	0.000238	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—JUN—psoriasis	1.15e-05	0.000236	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—NFKB1—psoriasis	1.14e-05	0.000235	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.14e-05	0.000234	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—IL6—psoriasis	1.14e-05	0.000234	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—IL6—psoriasis	1.13e-05	0.000233	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-A—psoriasis	1.13e-05	0.000232	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—IL6—psoriasis	1.13e-05	0.000232	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CRP—psoriasis	1.12e-05	0.000231	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—IL6—psoriasis	1.12e-05	0.000231	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.11e-05	0.000229	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CRP—psoriasis	1.1e-05	0.000227	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—NFKB1—psoriasis	1.1e-05	0.000227	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CARM1—psoriasis	1.1e-05	0.000226	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.08e-05	0.000223	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—PPARG—psoriasis	1.08e-05	0.000223	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CYP2S1—psoriasis	1.07e-05	0.00022	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CARM1—psoriasis	1.06e-05	0.000218	CbGpPWpGaD
Docetaxel—TUBB4B—Metabolism of proteins—CXCL8—psoriasis	1.06e-05	0.000218	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HLA-DRB1—psoriasis	1.06e-05	0.000218	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—IL6—psoriasis	1.05e-05	0.000217	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—IL6—psoriasis	1.05e-05	0.000217	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.05e-05	0.000217	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—IL6—psoriasis	1.04e-05	0.000215	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-E—psoriasis	1.04e-05	0.000213	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	1.04e-05	0.000213	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	1.03e-05	0.000212	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—IL6—psoriasis	1.03e-05	0.000212	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—STAT3—psoriasis	1.03e-05	0.000212	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—TP53—psoriasis	1.03e-05	0.000212	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.03e-05	0.000211	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—NFKBIA—psoriasis	1.02e-05	0.00021	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CCL20—psoriasis	1.02e-05	0.000209	CbGpPWpGaD
Docetaxel—BCL2—Immune System—ICAM1—psoriasis	1.02e-05	0.000209	CbGpPWpGaD
Docetaxel—BCL2—Immune System—NFKBIA—psoriasis	1.01e-05	0.000207	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.92e-06	0.000204	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—ICAM1—psoriasis	9.9e-06	0.000204	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—NFKBIA—psoriasis	9.82e-06	0.000202	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CARM1—psoriasis	9.65e-06	0.000199	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CARM1—psoriasis	9.57e-06	0.000197	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—CAT—psoriasis	9.54e-06	0.000196	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—TYK2—psoriasis	9.48e-06	0.000195	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—VEGFA—psoriasis	9.4e-06	0.000193	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	9.34e-06	0.000192	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—TP53—psoriasis	9.28e-06	0.000191	CbGpPWpGaD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.02e-06	0.000186	CbGpPWpGaD
Docetaxel—EGFR—Immune System—SOCS1—psoriasis	8.66e-06	0.000178	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—TP53—psoriasis	8.52e-06	0.000175	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—IL6—psoriasis	8.49e-06	0.000175	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—TYK2—psoriasis	8.37e-06	0.000172	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.29e-06	0.000171	CbGpPWpGaD
Docetaxel—BCL2—Immune System—TYK2—psoriasis	8.25e-06	0.00017	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	7.98e-06	0.000164	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—psoriasis	7.79e-06	0.00016	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NDUFA5—psoriasis	7.74e-06	0.000159	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IFNG—psoriasis	7.73e-06	0.000159	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CD8A—psoriasis	7.68e-06	0.000158	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CD4—psoriasis	7.57e-06	0.000156	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CD4—psoriasis	7.46e-06	0.000154	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—APOE—psoriasis	7.42e-06	0.000153	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—NFKB1—psoriasis	7.39e-06	0.000152	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-B—psoriasis	7.39e-06	0.000152	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—CD4—psoriasis	7.27e-06	0.00015	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.24e-06	0.000149	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—IL6—psoriasis	7.18e-06	0.000148	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—IL6—psoriasis	6.93e-06	0.000143	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CARM1—psoriasis	6.92e-06	0.000142	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-A—psoriasis	6.85e-06	0.000141	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—JUN—psoriasis	6.78e-06	0.00014	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CAT—psoriasis	6.75e-06	0.000139	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—VEGFA—psoriasis	6.71e-06	0.000138	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HLA-A—psoriasis	6.71e-06	0.000138	CbGpPWpGaD
Docetaxel—BCL2—Immune System—JUN—psoriasis	6.68e-06	0.000137	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—STAT3—psoriasis	6.64e-06	0.000137	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP2S1—psoriasis	6.58e-06	0.000136	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CRP—psoriasis	6.53e-06	0.000134	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CAT—psoriasis	6.53e-06	0.000134	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—NFKB1—psoriasis	6.53e-06	0.000134	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—IL6—psoriasis	6.5e-06	0.000134	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PPARG—psoriasis	6.46e-06	0.000133	CbGpPWpGaD
Docetaxel—BCL2—Immune System—NFKB1—psoriasis	6.43e-06	0.000132	CbGpPWpGaD
Docetaxel—EGFR—Disease—HLA-A—psoriasis	6.32e-06	0.00013	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—NFKB1—psoriasis	6.27e-06	0.000129	CbGpPWpGaD
Docetaxel—ABCC1—Disease—APOE—psoriasis	6.26e-06	0.000129	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HLA-DRB1—psoriasis	6.25e-06	0.000129	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.2e-06	0.000128	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ICAM1—psoriasis	6e-06	0.000124	CbGpPWpGaD
Docetaxel—EGFR—Immune System—NFKBIA—psoriasis	5.96e-06	0.000123	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CAT—psoriasis	5.94e-06	0.000122	CbGpPWpGaD
Docetaxel—EGFR—Disease—APOE—psoriasis	5.9e-06	0.000121	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CAT—psoriasis	5.89e-06	0.000121	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NOS2—psoriasis	5.83e-06	0.00012	CbGpPWpGaD
Docetaxel—BCL2—Immune System—STAT3—psoriasis	5.78e-06	0.000119	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—TNF—psoriasis	5.75e-06	0.000118	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SOCS1—psoriasis	5.6e-06	0.000115	CbGpPWpGaD
Docetaxel—EGFR—Disease—NOS2—psoriasis	5.5e-06	0.000113	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.47e-06	0.000113	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—TYK2—psoriasis	5.34e-06	0.00011	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—APOE—psoriasis	5.24e-06	0.000108	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CARM1—psoriasis	5.22e-06	0.000107	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—APOE—psoriasis	5.07e-06	0.000104	CbGpPWpGaD
Docetaxel—EGFR—Immune System—TYK2—psoriasis	4.88e-06	0.0001	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TYK2—psoriasis	4.78e-06	9.83e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—CXCL8—psoriasis	4.65e-06	9.57e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—IL6—psoriasis	4.64e-06	9.54e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—APOE—psoriasis	4.61e-06	9.49e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—APOE—psoriasis	4.57e-06	9.41e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IFNG—psoriasis	4.57e-06	9.4e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PPARG—psoriasis	4.57e-06	9.4e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—TYK2—psoriasis	4.5e-06	9.27e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PPARG—psoriasis	4.42e-06	9.09e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CD4—psoriasis	4.41e-06	9.08e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CD4—psoriasis	4.32e-06	8.89e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CAT—psoriasis	4.25e-06	8.75e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—LEP—psoriasis	4.13e-06	8.5e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—APOE—psoriasis	4.13e-06	8.5e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—IL6—psoriasis	4.1e-06	8.43e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—CD4—psoriasis	4.07e-06	8.38e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IL6—psoriasis	4.04e-06	8.3e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PPARG—psoriasis	4.02e-06	8.27e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PPARG—psoriasis	3.98e-06	8.2e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—JUN—psoriasis	3.95e-06	8.13e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NFKBIA—psoriasis	3.85e-06	7.92e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—NFKB1—psoriasis	3.8e-06	7.82e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—STAT3—psoriasis	3.42e-06	7.03e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—STAT3—psoriasis	3.35e-06	6.89e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—APOE—psoriasis	3.31e-06	6.8e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CARM1—psoriasis	3.22e-06	6.62e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CAT—psoriasis	3.21e-06	6.61e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TYK2—psoriasis	3.15e-06	6.49e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—STAT3—psoriasis	3.15e-06	6.49e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PPARG—psoriasis	2.88e-06	5.93e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CXCL8—psoriasis	2.75e-06	5.65e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL6—psoriasis	2.61e-06	5.37e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—JUN—psoriasis	2.55e-06	5.25e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—APOE—psoriasis	2.49e-06	5.13e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NFKB1—psoriasis	2.46e-06	5.06e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL6—psoriasis	2.39e-06	4.91e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—IL6—psoriasis	2.34e-06	4.81e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—VEGFA—psoriasis	2.23e-06	4.59e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—STAT3—psoriasis	2.21e-06	4.54e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—IL6—psoriasis	2.2e-06	4.53e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PPARG—psoriasis	2.17e-06	4.47e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CAT—psoriasis	1.98e-06	4.07e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—psoriasis	1.69e-06	3.47e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL6—psoriasis	1.54e-06	3.17e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—APOE—psoriasis	1.54e-06	3.16e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PPARG—psoriasis	1.34e-06	2.75e-05	CbGpPWpGaD
